These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32146431)

  • 1. Lichenoid rash: A new side effect of oral Cladribine.
    Aruta F; Iovino A; Costa C; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2020 Jun; 41():102023. PubMed ID: 32146431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
    Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on cladribine for relapsing-remitting multiple sclerosis.
    Holmøy T; Torkildsen Ø; Myhr KM
    Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cladribine for multiple sclerosis.
    Drug Ther Bull; 2018 Feb; 56(2):21-24. PubMed ID: 29449328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.
    Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B
    Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
    Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
    Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
    Cook S; Vermersch P; Comi G; Giovannoni G; Rammohan K; Rieckmann P; Sørensen PS; Hamlett A; Miret M; Weiner J; Viglietta V; Musch B; Greenberg SJ;
    Mult Scler; 2011 May; 17(5):578-93. PubMed ID: 21228029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
    Schmidt S
    Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
    Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
    Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 11. Disseminated nocardiosis after cladribine treatment for relapsing remitting multiple sclerosis: a case report.
    Deana C; Bagatto D; Battezzi A; Pecori D; Lorenzut S; Tuniz F
    J Neurol; 2022 Aug; 269(8):4557-4559. PubMed ID: 35352170
    [No Abstract]   [Full Text] [Related]  

  • 12. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
    Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
    N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
    Gummi R; Walsh RD; Ahmad B
    Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
    Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
    Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.
    Hermann R; Litwin JS; Friberg LE; Dangond F; Munafo A
    Br J Clin Pharmacol; 2019 Jul; 85(7):1484-1494. PubMed ID: 30883839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM
    N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study.
    Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eyebrow alopecia associated with cladribine treatment for multiple sclerosis.
    Budimkic MS; Ivanovic J; Momcilovic N; Mesaros S; Drulovic J
    Neurol Sci; 2023 Oct; 44(10):3735-3736. PubMed ID: 37249666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.